The number of new psychoactive substances (NPS) has increased significantly, especially within the last 5 years. The EMCDDA conducts risks assessments of such substances, especially in relation to serious adverse events. Examination of the individual health risks of a substance is a fundamental requirement of the process. Based on a number of considerations, the Toxicological Significance Score has been developed to support the risk assessment of NPS by allowing the role of a substance in deaths to be better assessed and classified.
No takes yet. Share an insight, caveat, or question.
Elliott et al. (2017) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: